[ad_1]
On November 20, Reuters reported that the European Union agreed to pay more than US $ 10 billion (about 65.74 billion yuan) to buy hundreds of millions of doses of the new corona vaccine from Pfizer and BioNTech. Currently, the EU and related pharmaceutical companies have declined to comment on this news.
Affected by this good news, US stocks rose nearly 6% before the market and Pfizer Pharmaceuticals was up almost 2% before the market.
Since the beginning of this year, BioNTech’s share price has soared 180%.
The EU can pay more than 60 billion
Buy COVID-19 Vaccine from Pfizer and BioNTech
On November 20, Reuters reported that the EU could pay more than US $ 10 billion (about 65.74 billion yuan) to obtain hundreds of millions of doses of Pfizer / BioNTech and CureVac’s new corona vaccine.
The official said that the European Union agreed to buy vaccines developed jointly by Pfizer Pharmaceuticals and German Biotech at a price of 15.5 euros (about RMB 121) per dose. This means that if 200 million doses of vaccine are purchased, the total price will amount to 3.1 billion euros (about 24.2 billion yuan). Under the deal, if 100 million optional doses are purchased, the total price will reach 4.65 billion euros (about RMB 36.3 billion yuan).
According to Reuters, according to the latest price information released, the EU buys each dose of vaccine at a lower price than the US In addition, according to the agreement signed between the European Union and Pfizer Pharmaceuticals, once they distribute the dose of vaccine agreed to the United States, the European Union will receive compensation.
Furthermore, considering that the first batch of 225 million doses of vaccines is discounted, the EU agreed to pay € 10 (almost US $ 12) for each dose of the CureVac vaccine. The company previously priced it at 12 euros. According to the official, the company promised to begin supplying vaccines at the end of March.
Previous news had said that the European Commission signed another vaccine contract with the European company CureVac on November 7. Under the contract, the EU will be able to obtain up to 405 million doses of the company’s vaccine. According to Reuters, if the price of each vaccine remains at 10 euros, the EU will pay 4.05 billion euros ($ 4.8 billion) for 405 million doses of vaccine.
95% Effective! Famous American Epidemiologists Questioned
On November 18, the US pharmaceutical company Pfizer announced that the vaccine developed jointly by it and the German biotechnology company BioNTech has an effective rate of 95% in the analysis of final data from clinical trials and has fulfilled the requirements to request authorization. for emergency use. It will be in a few days. Submit a request to the regulatory authority internally.
Previously, Pfizer stated that its new corona vaccine can prevent 90% of infections and is expected to apply for emergency use authorization by the end of November. If the application is successful, it means that the vaccine may be available in the United States later this year.
According to CCTV, the Canadian Broadcasting Corporation CBC reported that regarding the two companies they recently announced the development of a new corona vaccine with an efficiency of more than 90%, famous American infectious disease scientist Anthony Fauci said in an interview with the media. : “If there is an effective vaccine that is 75% effective, I would be very happy. I certainly hope there is a more effective vaccine, but frankly, I don’t have high hopes.”
Fauci further noted, “Using a new platform to test two vaccines is different from previous practices. This platform has never been used to test vaccines that have been approved and have such high efficacy.”
Fauci also mentioned that looking at the world, the epidemic is getting worse, with few exceptions. The spread of the epidemic in the EU and the United States is not over yet. Canada has done better prevention and control, but now it is also in trouble, with a lot of community spread. Not only that, there are now many asymptomatic infections. If large-scale testing is not done, or only people with symptoms are evaluated, these asymptomatic spreaders will be lost.
European Union Approves New BioNTech and Moderna Corona Vaccines in December
According to news from Bloomberg, on November 20, the head of the European Commission stated that the new corona vaccines from BioNTech and Moderna are expected to obtain a conditional marketing license from the EU next month.
On November 19, the president of the European Commission, Von der Lein, stated that the European Medicines Agency is in contact with the United States Food and Drug Administration to evaluate the new corona vaccine every day in order to “synchronize” the evaluation. If all goes well, the European Medicines Agency will tell us that BioNTech and Moderna can obtain a conditional marketing authorization at the end of December 2020.
The market believes that if European regulators can quickly approve the vaccine, countries are expected to lift the lockdown as soon as possible and the uncertainty of the European economic outlook will also be reduced.
At present, the EU has confirmed the purchase of up to 300 million doses of Pfizer and BioNTech vaccines, and has also signed supply agreements with crown vaccine development startups such as AstraZeneca, Sanofi, Johnson & Johnson and CureVac NV. . According to the Duke University Center for Global Health Innovation database, the EU currently has orders for around 1.2 billion doses of vaccines, but it is not yet clear how this will be distributed among member states.
Von der Lein said the European Commission “hopes to reach a vaccine supply deal with Moderna soon”.
On November 18, Pfizer PFE.N and BioNTech declared that their new crown vaccine could receive emergency clearance from the United States and Europe next month. The final test results announced above show that the vaccine is as effective as 95% and has no serious side effects. .
BioNTech CEO Ugur Sahin told Reuters that the US Food and Drug Administration could approve emergency use in mid-December. He added that the EU can get conditional approval in the second half of December.
